LAUSR

The challenges involved in the diagnosis of cardiac sarcoidosis are significant; however once the diagnosis has been successfully made, the journey has only just begun. Assessing severity of cardiac sarcoidosis (CS) may be crucial in predicting the clinical course, thereby guiding initial therapy—both medical and device therapy—and is often subsequently helpful in evaluating response to such therapies. If we could establish reliable and reproducible markers of disease severity which correlate with adverse outcomes, a validated severity index could be utilized at the time of diagnosis to help risk stratify patients, and guide therapy; either towards more aggressive immunosuppression or away fromunnecessary intervention in low risk disease. The current method of assessing severity is based mostly on expert opinion. There are no practice guidelines to assist in risk stratification, and there are a number of mostly clinical parameters that are utilized.